Committee advances bill to keep psilocybin classified until FDA action

A House committee voted to recommend passage of House Bill 382 on a voice vote after Representative Stevens described the bill as a temporary measure to manage psilocybin if federal approval arrives.

Representative Stevens, who introduced the measure, told the committee that the bill is intended to give the Board of Pharmacy “emergency powers” so regulators can place newly approved forms of psilocybin into an appropriate controlled‑substance class until the Legislature can act next year. "Psilocybin... is a drug that comes from mushrooms," Stevens said, and said it is being tested for severe depression and post‑traumatic stress disorder.

The bill responds to the annual drug‑update process the committee uses to assign drugs to controlled‑substance classes. Stevens said the committee moves drugs when the Board of Pharmacy and related agencies request changes and that the committee typically updates classifications once a year.

Committee members asked only procedural questions, and a member made a motion recommending the bill move forward; the committee recorded the measure as having "do pass" recommendation (LC339807S) following a voice vote. No roll‑call tally or named mover and seconder were recorded in the transcript.

The bill as presented does not change how psilocybin will be classified permanently; it places a temporary administrative mechanism in place pending FDA action and a later legislative rescheduling, the sponsor said.

No legal citation was introduced during the discussion beyond references to the U.S. Food and Drug Administration and the Board of Pharmacy's routine drug‑update authority.

The committee advanced the bill without additional amendments and recorded a do‑pass recommendation.